Methotrexat Accord (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, reducing the production of tetrahydrofolate. This limits the synthesis of nucleotides needed for DNA, RNA, and protein formation, thereby inhibiting the growth of rapidly proliferating cells such as cancer cells and activated immune cells.

The specific dose of Methotrexat Accord is determined by the prescribing clinician based on the patient’s diagnosis, disease severity, body surface area, renal and hepatic function, and treatment protocol. Only a qualified healthcare professional should set the dosing regimen.

Methotrexat Accord is classified as pregnancy category X, meaning it is contraindicated in pregnancy due to a high risk of fetal harm. It is also not recommended while breastfeeding because it can be excreted in milk and affect the infant. Effective contraception is required for both men and women of reproductive potential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Methotrexat Accord (methotrexate) is a widely used antimetabolite with a broad therapeutic range, covering both oncology and autoimmune diseases. Compared with newer agents such as leflunomide or biologics, methotrexate is generally less expensive but requires more laboratory monitoring for toxicity. Its efficacy in rheumatoid arthritis and certain cancers remains well established.

Methotrexat Accord should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly sealed when not in use.

Methotrexat Accord is supplied as a sterile injectable solution and can be given via intra‑arterial, intramuscular, or intravenous routes, depending on the clinical indication and prescribing physician’s judgment. Administration is performed by qualified healthcare professionals in a controlled setting.

The most serious risks include bone‑marrow suppression leading to pancytopenia, severe liver toxicity, pulmonary fibrosis, renal impairment, and life‑threatening infections. Patients should be monitored regularly for hematologic, hepatic, and renal parameters, and any signs of infection or respiratory distress require immediate medical attention.

Methotrexat Accord is contraindicated in pregnant women, individuals with severe hepatic or renal impairment, patients with known hypersensitivity to methotrexate, and those receiving live vaccines. It should also be avoided in patients with uncontrolled infections or pre‑existing bone‑marrow disorders.